Rag2 Knockout/Transgenic LCMV-P14 T Cell Receptor

Constitutive Knockout/Random Transgenic

Rag2 Knockout/Transgenic LCMV-P14 T Cell Receptor Constitutive Knockout/Random Transgenic Mouse Model
This line is cryopreserved and requires cryorecovery.

  • Model #
  • Genotype
  • Nomenclature
  • 14983-F
    B6;B10-Rag2tm1Fwa Tg(TcrLCMV)327Sdz
  • 14983-M
    B6;B10-Rag2tm1Fwa Tg(TcrLCMV)327Sdz
The Rag2 Knockout/Transgenic LCMV-P14 T Cell Receptor line is homozygous for a transgene that encodes a T cell receptor that is specific for a peptide (P14) from the lymphocytic choriomeningitis virus (LCMV) presented by the MHC class I molecule H2-Db. It is also deficient in the Rag2 gene (recombinase activating gene 2) and therefore does not develop endogenous mature T or B cells. Almost all the peripheral T cells are CD8+ and express the transgenic TCR. The mice are useful for in vitro studies of CD8+ T cell activation and differentiation to cytotoxic T lymphocytes and as a source of donor cells for adoptive transfer into B10 mice for in vivo studies of inflammation, tolerance, and anti-viral responses.


The Transgenic LCMV-P14 T Cell Receptor transgenic mouse was made by Dr. Hanspeter Pircher and colleagues in 1989 at the Department of Experimental Pathology in Zurich, Switzerland. The transgenic line was generated by coinjection of the P14 Tcrα and Tcrβ gene constructs into (C57BL/6 x DBA/2)F2 fertilized eggs. The male founder 327 who had 10-20 copies of both transgenes integrated onto the same chromosome was crossed to a C57BL/6 female. The line was subsequently backcrossed to C57BL/6 up to N10 and then intracrossed to establish a homozygous line. These mice were brought to Taconic in May of 1997 by Dr. B.J. Fowlkes and embryo transfer-derived into the NIAID colony. In 1998 this strain was crossed twice to homozygous Rag2 knockout mice which were backcrossed 12 generations to C57BL/10 (N12). That Rag2 strain had been developed at Taconic by Dr. Ron Schwartz of NIAID from the 129S6 founder mice created in 1992 in the laboratory of Dr. Fred Alt by Dr. Y Shinkai. The mice were again made homozygous for the transgene by intracrossing followed by selection using test crosses to outbred mice and typing for high levels of expression of the Vβ 8.1 transgene and the absence of B220+ cells in order to generate line 4113. Line 4113 was then backcrossed six additional generations to the C57BL/10-Rag2tm1Fwa line to generate line 4356. Line 4356 was crossed to model RAGN12 to generate model 14983.


This line is cryopreserved and requires cryorecovery.





Initial Publication:

Pircher H, Burki K, Lang R, Hengartner H, Zinkernagel RM; Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen; Nature 1989 Nov 30;342(6249):559-561

Shinkai, Y, Rathbun, G, Lam, KP, Oltz, EM, Stewart, V, Mendelsohn, M, Charron, J, Datta, M, Young, F, Stall, AM, and Alt, FW. (1992) RAG-2-Deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement, Cell, 68: 855-867.

This line is available for immediate cryorecovery. A limited breeding agreement with a license fee is required. Current limited breeding agreement fees are $4,000/€3400 per year for non-profit users and $9,000/€9650 per year for for-profit users. Cryorecovery fees are additional.